The treatment of early-stage disease

Seminars in Radiation Oncology

Volumn 20, Issue 3, 2010, Pages 178-185

  Robinson, Clifford G ^a   Bradley, Jeffrey D ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; INTERMETHOD COMPARISON; LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MULTIPLE CYCLE TREATMENT; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; REVIEW; RISK REDUCTION; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT FAILURE;

BRACHYTHERAPY; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; LUNG; LUNG NEOPLASMS;

EID: 77954838868     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2010.01.004     Document Type: Review

References (89)

1. Cancer Facts and Figures 2009 2009, American Cancer Society, Atlanta, GA.
2. Groome P.A., Bolejack V., Crowley J.J. The IASLC lung cancer staging project: Validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007, 2:694-705.
3. Wilson D.O., Weissfeld J.L., Fuhrman C.R. The Pittsburgh Lung Screening Study (PLuSS): Outcomes within 3 years of a first computed tomography scan. Am J Respir Crit Care Med 2008, 178:956-961.
4. Goldstraw P., Crowley J., Chansky K. The IASLC lung cancer staging project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007, 2:706-714.
5. Clinical Practice Guidelines in Oncology, 2009 National Comprehensive Cancer Network (NCCN), Accessed September 20, 2009. http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf.
6. Guidelines: Guidelines on the selection of patients with lung cancer for surgery. Thorax 2001, 56:89-108. BTS.
7. Colice G.L., Shafazand S., Griffin J.P. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007, 132:161S-177S.
8. Myrdal G., Gustafsson G., Lambe M. Outcome after lung cancer surgery. Factors predicting early mortality and major morbidity. Eur J Cardio Thorac Surg 2001, 20:694-699.
9. Goodney P.P., Lucas F.L., Stukel T.A. Surgeon specialty and operative mortality with lung resection. Ann Surg 2005, 241:179-184.
10. Rami-Porta R., Ball D., Crowley J. The IASLC lung cancer staging project: Proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007, 2:593-602.
11. Cerfolio R.J., Bryant A.S. Survival of patients with true pathologic stage I non-small cell lung cancer. Ann Thorac Surg 2009, 88:917-922.
12. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998, 352:257-263. PORT Meta-analysis Trialists Group.
13. Lally B.E., Zelterman D., Colasanto J.M. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 2006, 24:2998-3006.
14. Douillard J.Y., Rosell R., De Lena M. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (adjuvant Navelbine International Trialist Association [Anita]): A randomised controlled trial. Lancet Oncol 2006, 7:719-727.
15. Douillard J.Y., Rosell R., De Lena M. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: The adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys 2008, 72:695-701.
16. Trodella L., Granone P., Valente S. Adjuvant radiotherapy in non-small cell lung cancer with pathological stage I: Definitive results of a phase III randomized trial. Radiother Oncol 2002, 62:11-19.
17. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev 2005, PORT Meta-analysis Trialists Group, CD:002142.
18. Kelsey C.R., Marks L.B., Hollis D. Local recurrence after surgery for early stage lung cancer: An 11-year experience with 975 patients. Cancer 2009, 115. 5218-1527.
19. Choong C.K., Meyers B.F., Battafarano R.J. Lung cancer resection combined with lung volume reduction in patients with severe emphysema. J Thorac Cardiovasc Surg 2004, 127:1323-1331.
20. Linden P.A., Bueno R., Colson Y.L. Lung resection in patients with preoperative FEV1 <35% predicted. Chest 2005, 127:1984-1990.
21. Shennib H., Bogart J., Herndon J.E. Video-assisted wedge resection and local radiotherapy for peripheral lung cancer in high-risk patients: The Cancer and Leukemia Group B (CALGB) 9335, a phase II, multi-institutional Cooperative Group study. J Thorac Cardiovasc Surg 2005, 129:813-818.
22. Ginsberg R.J., Rubinstein L.V. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995, 60:615-622.
23. Sugi K., Kobayashi S., Sudou M. Long-term prognosis of video-assisted limited surgery for early lung cancer. Eur J Cardiothorac Surg 2009, 37:456-460.
24. Phase III randomized study of lobectomy versus sublobar resection in patients with small peripheral stage IA non-small cell Accessed September 20, 2009. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=555324%26version=HealthProfessional%26protocolsearchid=6789389.
25. Voynov G., Heron D.E., Lin C.J. Intraoperative (125)I VICRYL Mesh brachytherapy after sublobar resection for high-risk stage I non-small cell lung cancer. Brachytherapy 2005, 4:278-285.
26. Santos R., Colonias A., Parda D. Comparison between sublobar resection and 125Iodine brachytherapy after sublobar resection in high-risk patients with stage I non-small-cell lung cancer. Surgery 2003, 134:691-697.
27. Lee W., Daly B.D., DiPetrillo T.A. Limited resection for non-small cell lung cancer: Observed local control with implantation of I-125 brachytherapy seeds. Ann Thorac Surg 2003, 75:237-242.
28. Phase III randomized study of sublobar resection with versus without intraoperative brachytherapy in high-risk patients with stage I non-small cell Accessed September 20, 2009. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=422346%26version=HealthProfessional%26protocolsearchid=6765732.
29. Winton T., Livingston R., Johnson D. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005, 352:2589-2597.
30. Arriagada R., Bergman B., Dunant A. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004, 350:351-360.
31. Waller D., Peake M.D., Stephens R.J. Chemotherapy for patients with non-small cell lung cancer: The surgical setting of the Big Lung Trial. Eur J Cardio Thorac Surg 2004, 26:173-182.
32. Scagliotti G.V., Fossati R., Torri V. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 2003, 95:1453-1461.
33. Pignon J.P., Tribodet H., Scagliotti G.V. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008, 26:3552-3559.
34. Strauss G., Maddaus M., Johnstone D. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage Ib non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol (Meeting Abstracts) 2004, 22:7019.
35. Strauss G.M., Herndon J.E., Maddaus M.A. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group study groups. J Clin Oncol 2008, 26:5043-5051.
36. Goodgame B., Viswanathan A., Zoole J. Risk of recurrence of resected stage I non-small cell lung cancer in elderly patients as compared with younger patients. J Thorac Oncol 2009, 4:1370-1374.
37. Chen H.Y., Yu S.L., Chen C.H. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007, 356:11-20.
38. Potti A., Mukherjee S., Petersen R. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006, 355:570-580.
39. Phase III randomized study of adjuvant chemotherapy versus observation in patients with stage I non-small cell Accessed September 20, 2009. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=636895%26version=HealthProfessional%26protocolsearchid=6769410.
40. Bach P.B., Cramer L.D., Warren J.L. Racial differences in the treatment of early-stage lung cancer. N Engl J Med 1999, 341:1198-1205.
41. McGarry R.C., Song G., des Rosiers P. Observation-only management of early stage, medically inoperable lung cancer: Poor outcome. Chest 2002, 121:1155-1158.
42. Raz D.J., Zell J.A., Ou S.H. Natural history of stage I non-small cell lung cancer: Implications for early detection. Chest 2007, 132:193-199.
43. Werner-Wasik M., Xiao Y., Pequignot E. Assessment of lung cancer response after nonoperative therapy: Tumor diameter, bidimensional product, and volume. A serial CT scan-based study. Int J Radiat Oncol Biol Phys 2001, 51:56-61.
44. Qiao X., Tullgren O., Lax I. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer 2003, 41:1-11.
45. Chen M., Hayman J.A., ten Haken R.K. Long-term results of high-dose conformal radiotherapy for patients with medically inoperable T1-3N0 non-small-cell lung cancer: Is low incidence of regional failure due to incidental nodal irradiation?. Int J Radiat Oncol Biol Phys 2006, 64:120-126.
46. Hayman J.A., Martel M.K., ten Haken R.K. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: Update of a phase I trial. J Clin Oncol 2001, 19:127-136.
47. Bradley J., Graham M.V., Winter K. Toxicity and outcome results of RTOG 9311: A phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2005, 61:318-328.
48. Rosenzweig K.E., Fox J.L., Yorke E. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer 2005, 103:2118-2127.
49. Bogart J., Watson D., Seagren S. Accelerated conformal radiotherapy for stage I non-small cell lung cancer (NSCLC) in patients with pulmonary dysfunction: A CALGB phase I study. J Clin Oncol (Meeting Abstracts) 2007, 25:7556.
50. Radiation therapy in treating patients with stage I or stage II non-small cell lung cancer that cannot Be removed by surgery Accessed September 20, 2009. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=652051%26version=HealthProfessional%26protocolsearchid=6789406.
51. Phase II study of hypofractionated 3-dimensional conformal radiotherapy in patients with newly diagnosed stage I-III non-small cell Accessed September 20, 2009. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=639199%26version=HealthProfessional%26protocolsearchid=6784955.
52. Sulman E.P., Komaki R., Klopp A.H. Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer. Radiol Oncol 2009, 4:5.
53. Bradley J.D., Wahab S., Lockett M.A. Elective nodal failures are uncommon in medically inoperable patients with stage I non-small-cell lung carcinoma treated with limited radiotherapy fields. Int J Radiat Oncol Biol Phys 2003, 56:342-347.
54. Zhao L., Chen M., ten Haken R. Three-dimensional conformal radiation may deliver considerable dose of incidental nodal irradiation in patients with early stage node-negative non-small cell lung cancer when the tumor is large and centrally located. Radiother Oncol 2007, 82:153-159.
55. Carey S.M., Katz A., Constine L.S. Stereotactic body radiation therapy for extracranial oligometastases: Does the sword have a double edge?. Semin Radiat Oncol 2006, 16:67-76.
56. Brock J., Ashley S., Bedford J. Review of hypofractionated small volume radiotherapy for early-stage non-small cell lung cancer. Clin Oncol R Coll Radiol 2008, 20:666-676.
57. Lagerwaard F.J., Haasbeek C.J., Smit E.F. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008, 70:685-692.
58. Baumann P., Nyman J., Hoyer M. Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer-A first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiother Oncol 2008, 88:359-367.
59. Koto M., Takai Y., Ogawa Y. A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer. Radiother Oncol 2007, 85:429-434.
60. Takeda A., Sanuki N., Kunieda E. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm. Int J Radiat Oncol Biol Phys 2009, 73:442-448.
61. Timmerman R., McGarry R., Yiannoutsos C. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006, 24:4833-4839.
62. Timmerman R., Papiez L., McGarry R. Extracranial stereotactic radioablation: Results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003, 124:1946-1955.
63. Timmerman RD, Paulus R, Galvin J: Stereotactic body radiation therapy for medically inoperable early-stage lung cancer patients: Analysis of RTOG 0236: Presented at the 51st Annual Meeting of the American Society for Radiation Oncology. Chicago, IL, 2009.
64. Nagata Y., Hiraoka M., Mizowaki T. Survey of stereotactic body radiation therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group. Int J Radiat Oncol Biol Phys 2009, 75:343-347.
65. Hara R., Itami J., Kondo T. Clinical outcomes of single-fraction stereotactic radiation therapy of lung tumors. Cancer 2006, 106:1347-1352.
66. Hof H., Muenter M., Oetzel D. Stereotactic single-dose radiotherapy (radiosurgery) of early stage nonsmall-cell lung cancer (NSCLC). Cancer 2007, 110:148-155.
67. Phase II randomized study of single fraction versus multiple fraction stereotactic body radiotherapy in medically inoperable patients with stage I peripheral non-small cell Accessed September 20, 2009. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=652101%26version=HealthProfessional%26protocolsearchid=6830553.
68. Onishi H., Shirato H., Nagata Y. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007, 2:S94-S100.
69. Kirkpatrick J.P., Meyer J.J., Marks L.B. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol 2008, 18:240-243.
70. Brenner D.J. The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction. Semin Radiat Oncol 2008, 18:234-239.
71. Park C., Papiez L., Zhang S. Universal survival curve and single fraction equivalent dose: Useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 2008, 70:847-852.
72. Flickinger J.C., Kondziolka D., Maitz A.H. An analysis of the dose-response for arteriovenous malformation radiosurgery and other factors affecting obliteration. Radiother Oncol 2002, 63:347-354.
73. Fuks Z., Kolesnick R. Engaging the vascular component of the tumor response. Cancer Cell 2005, 8:89-91.
74. Dalerba P., Cho R.W., Clarke M.F. Cancer stem cells: Models and concepts. Annu Rev Med 2007, 58:267-284.
75. Ch'ang H.J., Maj J.G., Paris F. ATM regulates target switching to escalating doses of radiation in the intestines. Nat Med 2005, 11:484-490.
76. Phase I/II study of stereotactic body radiotherapy in medically inoperable patients with centrally located stage I non-small cell Accessed September 20, 2009. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=613524%26version=HealthProfessional%26protocolsearchid=6830592.
77. Gay H.A., Sibata C.H., Allison R.R. Isodose-based methodology for minimizing the morbidity and mortality of thoracic hypofractionated radiotherapy. Radiother Oncol 2009, 91:369-378.
78. Milano M.T., Constine L.S., Okunieff P. Normal tissue toxicity after small field hypofractionated stereotactic body radiation. Radiol Oncol 2008, 3:36.
79. Forquer J.A., Fakiris A.J., Timmerman R.D. Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: Dose-limiting toxicity in apical tumor sites. Radiother Oncol 2009, 93:408-413.
80. Borst G.R., Ishikawa M., Nijkamp J. Radiation pneumonitis in patients treated for malignant pulmonary lesions with hypofractionated radiation therapy. Radiother Oncol 2009, 91:307-313.
81. Ricardi U., Filippi A.R., Guarneri A. Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy. Acta Oncol 2009, 48:571-577.
82. Dunlap N.E., Cai J., Biedermann G.B. Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2009, 76:796-801.
83. Stephans KL, Djemil T, Tendulkar RD: Prediction of chest wall toxicity after lung stereotactic body radiotherapy (SBRT): Presented at the 51st Annual Meeting of the American Society for Radiation Oncology. Chicago, IL, November 1-5, 2009.
84. Pettersson N., Nyman J., Johansson K.A. Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy of non-small cell lung cancer: A dose- and volume-response analysis. Radiother Oncol 2009, 91:360-368.
85. Uematsu M., Shioda A., Suda A. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: A 5-year experience. Int J Radiat Oncol Biol Phys 2001, 51:666-670.
86. Denlinger C, Bradley JD, El Naqa IM: Propensity matched comparison of surgery vs. stereotactic body radiation therapy in early stage lung cancer: Presented at the 89th Annual Meeting of the American Association for Thoracic Surgery. Boston, MA, May 9-13, 2009.
87. Phase II study of stereotactic body radiotherapy in patients with resectable stage I or II non-small cell Accessed September 20, 2009. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=571744%26version=HealthProfessional%26protocolsearchid=6811460.
88. Trial of either surgery or stereotactic radiotherapy for early stage (IA) Accessed September 20, 2009. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=597713%26version=HealthProfessional%26protocolsearchid=6784945.
89. International randomized study to compare CyberKnife stereotactic radiotherapy with surgical resection in stage I non-small cell Accessed September 20, 2009. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=635570%26version=HealthProfessional%26protocolsearchid=6784945.